Biotechnology - Neurological, Generics


Current filters:


Popular Filters

1 to 25 of 3844 results

Actavis settles Celebrex patent challenge with Pfizer


Ireland-headquartered generic major Actavis has entered into an agreement with US pharma giant Pfizer…


Celgene beats expectations, despite profit downturn


US biotech firm Celgene saw its shares fall 3.3% to $140.05 in mid-morning trading after it posted first-quarter…


WuXi PharmaTech announces Management Appointments

WuXi PharmaTech announces Management Appointments


China’s WuXi PharmaTech (NYSE: WX) has announced that Dr Steve Yang has joined the company as Executive…

BiotechnologyBoardroomChinaPharmaceuticalWuXi PharmaTech

Hyperion Therapeutics to broaden orphan disease pipeline with buy of Israeli firm


US biotech firm Hyperion Therapeutics has entered into a definitive agreement to acquire Andromeda Biotech,…

Andromeda BiotechBiotechnologyDiabetesDiaPep277Hyperion TherapeuticsMergers & Acquisitions

CT Catapult to work with Athersys to advance European development of MultiStem therapy


The Cell Therapy Catapult, which is focused on the development of the UK cell therapy industry to increase…

AthersysBiotechnologyCell Therapy CatapultEuropeMarkets & MarketingResearch

Impax Laboratories appoints Frederick Wilkinson as President and CEO

Impax Laboratories appoints Frederick Wilkinson as President and CEO


US generic drugmaker Impax Laboratories (NASDAQ: IPXL) has announced the appointment of Frederick Wilkinson…

BiotechnologyBoardroomImpax LaboratoriesPharmaceuticalUSA

Lupin inks strategic biosimilars joint venture agreement with Yoshindo


Indian drugmaker Lupin has entered into a strategic joint venture agreement with Japanese pharma company,…

BiosimilarsBiotechnologyEnbrelInflammatory diseasesJapanLicensingLupinTakeda PharmaceuticalYoshindo

Biogen Idec 1st-qtr 2014 revenue leaps 51%, driven by Tecfidera and MS franchise


US biotech firm Biogen Idec first-quarter 2014 results today, including revenue of $2.1 billion, a 51%…

Biogen IdecBiotechnologyFinancialNeurologicalResearchTecfidera

Abbott may acquire one of Russia’s leading drugmakers for $240 million


The USA’s Abbott Laboratories is considering acquiring the 81.1 % stake in Veropharm, one of Russia’s…

Abbott LaboratoriesGenericsMergers & AcquisitionsRussiaVeropharm

Amgen's 1st-qtr 2014 disappoints, as net income falls 25%


Amgen, the world’s largest independent biotech firm by revenues, yesterday announced financial results…


Bristol-Myers Squibb and Samsung BioLogics expand manufacturing deal


US drug major Bristol-Myers Squibb and South Korea’s Samsung BioLogics revealed that they will increase…

Asia-PacificBiotechnologyBristol-Myers SquibbProductionSamsung BioLogics

Gilead 1st-qtr 2014 sales nearly double, fuelled by Sovaldi, as net income rockets


US antivirals major Gilead Sciences posted first-quarter 2014 results after markets closed yesterday,…

Anti-viralsBiotechnologyFinancialGilead SciencesSovaldi

Epizyme earns $4 million milestone under GSK collaboration


US clinical-stage biopharma firm Epizyme announced the achievement of the lead candidate milestone for…


AusBiotech to submit to Senate’s Australian innovation system inquiry


Trade group AusBiotech is preparing a submission, following the Senate's referral of an inquiry into…


Sentinel Oncology in deal with Oncothyreon worth a potential $174 million


UK-based small molecule drug discovered Sentinel Oncology has signed a collaboration agreement with the…

BiotechnologyLicensingOncologyOncothyreonResearchSentinel Oncology

Sanofi divests Cell Therapy and Regenerative Medicine business to Aastrom


US cardiovascular drug developer Aastrom Biosciences has entered into a definitive agreement to acquire…

Aastrom BiosciencesBiotechnologyMergers & AcquisitionsSanofi

US FDA clears pathway for Sarepta’s eteplirsen filing by year end


US RNA-based drug developer Sarepta Therapeutics it plans to submit a New Drug Application to the US…

BiotechnologyeteplirsenNorth AmericaRare diseasesRegulationSarepta TherapeuticsUSA

US Supreme Court denies Teva's request for injunction relating to Mylan’s generic Copaxone


The US Supreme Court Chief Justice Roberts has denied Israeli generics giant Teva Pharmaceutical Industries’…

CopaxoneGenericsLegalMylan LaboratoriesNeurologicalNorth AmericaPatentsTeva Pharmaceutical IndustriesUSA

Biogen Idec exercises option for Amunix’ XTENylated Factor VIII


US privately-held biotech firm Amunix Operating says that Biogen Idec has exercised its option to enter…

AmunixBiogen IdecBiotechnologyHematologyLicensing

NHS England agrees funding for Gilead’s hepatitis C drug Sovaldi


NHS England has approved an £18.7 million ($31.3 million) investment in a new drug for the treatment…

Anti-viralsBiotechnologyFinancialGilead SciencesHealthcareNorthern EuropeSovaldiUK

First Asian approval for ophthalmic drug Jetrea, in Malaysia


Belgian biotech firm ThromboGenics NV revealed today that Jetrea (ocriplasmin) has been approved in Malaysia…


Teva and Pfizer settle patent litigation over Celebrex


Israel-based Teva Pharmaceutical Industries says that its US subsidiary has settled a law suit with US…

Anti-Arthritics/RheumaticsCelebrexGenericsNorth AmericaPatentsPfizerTeva Pharmaceutical IndustriesUSA

1 to 25 of 3844 results

Back to top